Find information on thousands of medical conditions and prescription drugs.

Isosorbide

May refer to either of two medications used to treat angina pectoris: isosorbide dinitrate or isosorbide mononitrate. It may also refer to other isosorbide-based medicines used as osmotic diuretics.

Isosorbide is used to prevent or treat chest pain(angina). It works by relaxing the blood vessels to the heart so the blood and oxygen supply to the heart is increased. It comes in regular, sublingual, chewable, and extended release(long-acting) capsule to be taken by mouth.

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
Ibuprofen
Idarubicin
Idebenone
IFEX
Iloprost
Imatinib mesylate
Imdur
Imipenem
Imipramine
Imiquimod
Imitrex
Imodium
Indahexal
Indapamide
Inderal
Indocin
Indometacin
Infliximab
INH
Inosine
Intal
Interferon gamma
Intralipid
Invanz
Invirase
Iontocaine
Iotrolan
Ipratropium bromide
Iproniazid
Irbesartan
Iressa
Irinotecan
Isocarboxazid
Isoflurane
Isohexal
Isoleucine
Isomonit
Isoniazid
Isoprenaline
Isordil
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isotretinoin
Itraconazole
Ivermectin
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Update on outpatient treatment of systolic heart failure
From American Family Physician, 10/1/05 by Kevin Fiscella

TO THE EDITOR: I read with interest the article (1) by McConaghy and Smith in American Family Physician, on the outpatient treatment of systolic heart failure. I want to clarify two points. First, the authors correctly note that the Randomized Aldactone Evaluation Study (RALES) showed reductions in mortality and hospitalization in patients with congestive heart failure who received spironolactone (Aldactone). However, publication of these findings was associated with an abrupt increase in the rate of prescriptions for spironolactone and in hyperkalemia-associated morbidity and mortality. (2) Other studies (3,4) have reported much higher rates of drug discontinuation because of hyperkalemia than those reported in RALES, particularly in the presence of angiotensin-converting enzyme inhibitors. These differences highlight the challenge of translating findings from controlled trials into practice, and suggest the need for intensive monitoring of serum potassium levels in patients receiving spironolactone for this purpose.

Second, the authors correctly note that the first Vasodilator-Heart Failure Trial (V-HeFT I) showed no improvement in overall mortality in patients given a combination of hydralazine (Sorbitrate) plus isosorbide (Apresoline) dinitrate compared with those treated with enalapril (Vasotec). However, a subanalysis (5) showed benefit for blacks, and the recent African-American Heart Failure Trial (A-HeFT), (6) involving only blacks, showed a 43 percent reduction in all-cause mortality among patients receiving hydralazine plus isosorbide dinitrate in addition to standard therapy. Both drugs are available generically at modest cost.

REFERENCES

(1.) McConaghy JR, Smith SR. Outpatient treatment of systolic heart failure. Am Fam Physician 2004;70:2157-64.

(2.) Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51.

(3.) Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003;18:1814-9.

(4.) Witham MD, Gillespie ND, Struthers AD. Tolerability of spironolactone in patients with chronic heart failure--a cautionary message. Br J Clin Pharmacol 2004;58:554-7.

(5.) Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999;5:178-87.

(6.) Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57.

EDITOR'S NOTE: This letter was sent to the authors of "Outpatient Treatment of Systolic Heart Failure," who declined to reply.

KEVIN FISCELLA, M.D., M.P.H.

University of Rochester

1381 S. Ave.

Rochester, NY 14620

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Isosorbide
Home Contact Resources Exchange Links ebay